X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs CIPLA - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD CIPLA STRIDES SHASUN LTD/
CIPLA
 
P/E (TTM) x 15.2 44.3 34.4% View Chart
P/BV x 1.8 3.9 45.7% View Chart
Dividend Yield % 0.6 0.3 168.7%  

Financials

 STRIDES SHASUN LTD   CIPLA
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
CIPLA
Mar-17
STRIDES SHASUN LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,275622 205.0%   
Low Rs918458 200.3%   
Sales per share (Unadj.) Rs389.6181.9 214.2%  
Earnings per share (Unadj.) Rs28.012.9 217.3%  
Cash flow per share (Unadj.) Rs48.929.3 166.8%  
Dividends per share (Unadj.) Rs4.502.00 225.0%  
Dividend yield (eoy) %0.40.4 110.8%  
Book value per share (Unadj.) Rs303.1155.7 194.7%  
Shares outstanding (eoy) m89.42804.51 11.1%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.83.0 94.8%   
Avg P/E ratio x39.242.0 93.4%  
P/CF ratio (eoy) x22.418.4 121.7%  
Price / Book Value ratio x3.63.5 104.3%  
Dividend payout %16.115.5 103.5%   
Avg Mkt Cap Rs m98,036434,516 22.6%   
No. of employees `0005.823.0 25.2%   
Total wages/salary Rs m5,88126,338 22.3%   
Avg. sales/employee Rs Th6,005.96,349.1 94.6%   
Avg. wages/employee Rs Th1,014.01,143.0 88.7%   
Avg. net profit/employee Rs Th431.2449.3 96.0%   
INCOME DATA
Net Sales Rs m34,834146,302 23.8%  
Other income Rs m1,6862,287 73.7%   
Total revenues Rs m36,520148,589 24.6%   
Gross profit Rs m6,42824,758 26.0%  
Depreciation Rs m1,87213,229 14.1%   
Interest Rs m2,2691,594 142.4%   
Profit before tax Rs m3,97312,222 32.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m4-70 -5.2%   
Extraordinary Inc (Exp) Rs m-1,0060-   
Tax Rs m4701,798 26.1%   
Profit after tax Rs m2,50110,354 24.2%  
Gross profit margin %18.516.9 109.0%  
Effective tax rate %11.814.7 80.4%   
Net profit margin %7.27.1 101.4%  
BALANCE SHEET DATA
Current assets Rs m38,16587,370 43.7%   
Current liabilities Rs m30,40233,081 91.9%   
Net working cap to sales %22.337.1 60.1%  
Current ratio x1.32.6 47.5%  
Inventory Days Days7787 88.9%  
Debtors Days Days10462 167.7%  
Net fixed assets Rs m37,639111,567 33.7%   
Share capital Rs m8941,609 55.6%   
"Free" reserves Rs m26,210123,645 21.2%   
Net worth Rs m27,105125,254 21.6%   
Long term debt Rs m16,37736,454 44.9%   
Total assets Rs m81,168209,532 38.7%  
Interest coverage x2.88.7 31.7%   
Debt to equity ratio x0.60.3 207.6%  
Sales to assets ratio x0.40.7 61.5%   
Return on assets %5.95.7 103.1%  
Return on equity %9.28.3 111.6%  
Return on capital %12.18.5 141.8%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m13,46551,066 26.4%   
Fx outflow Rs m4,07617,678 23.1%   
Net fx Rs m9,38933,388 28.1%   
CASH FLOW
From Operations Rs m2,88123,824 12.1%  
From Investments Rs m-7,051-13,127 53.7%  
From Financial Activity Rs m3,382-13,239 -25.5%  
Net Cashflow Rs m-788-2,478 31.8%  

Share Holding

Indian Promoters % 27.7 16.0 173.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 37.8 12.2 309.8%  
FIIs % 8.6 23.7 36.3%  
ADR/GDR % 0.0 1.1 -  
Free float % 25.9 26.2 98.9%  
Shareholders   56,241 161,166 34.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare STRIDES SHASUN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Jan 19, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 5-YR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS